Atnahs
Pharmanovia is a life cycle management company committed to realizing the full potential of established medicines. They focus on improving patient outcomes by rediscovering, re-engineering, and strategically partnering to develop innovative therapies. Their mission is to make medicines fit for tomorrow and to improve lives globally, with a vision to be one of the world's fastest-growing global specialty pharma companies.
Industries
Nr. of Employees
medium (51-250)
Atnahs
Sovereign House, Miles Gray Road, Basildon, SS14 3FR, UK
Products
Inderal (propranolol)
Oral beta‑blocker (propranolol) for cardiovascular indications.
Tenormin (atenolol)
Oral beta‑blocker (atenolol) for cardiovascular indications.
Zestril (lisinopril) and Zestoretic (lisinopril + hydrochlorothiazide)
ACE inhibitor (lisinopril) and combination ACE inhibitor plus diuretic for hypertension management.
Bonviva / Bondronat (ibandronic acid)
Bisphosphonate for treatment and prevention of osteoporosis (oral and parenteral formulations referenced across portfolio).
Rocaltrol (calcitriol)
Active vitamin D (calcitriol) formulation for endocrine and bone‑related indications.
Synacthen (tetracosactide / tetracosactide acetate)
Synthetic ACTH analogue used in diagnostic and therapeutic contexts.
Inderal (propranolol)
Oral beta‑blocker (propranolol) for cardiovascular indications.
Tenormin (atenolol)
Oral beta‑blocker (atenolol) for cardiovascular indications.
Zestril (lisinopril) and Zestoretic (lisinopril + hydrochlorothiazide)
ACE inhibitor (lisinopril) and combination ACE inhibitor plus diuretic for hypertension management.
Bonviva / Bondronat (ibandronic acid)
Bisphosphonate for treatment and prevention of osteoporosis (oral and parenteral formulations referenced across portfolio).
Rocaltrol (calcitriol)
Active vitamin D (calcitriol) formulation for endocrine and bone‑related indications.
Synacthen (tetracosactide / tetracosactide acetate)
Synthetic ACTH analogue used in diagnostic and therapeutic contexts.
Services
Identification, negotiation and management of in‑licensing and out‑licensing deals to expand therapeutic portfolios.
Technical and commercial redevelopment of established medicines through reformulation, repurposing or new dosage forms to improve patient outcomes and extend product lifecycle.
Market entry and commercial execution services including in‑house sales force deployment, distributor management and regional go‑to‑market strategies.
Management of CMO relationships for API manufacture, tolling and packing, and coordination with 3PLs and specialist distributors for global logistics.
Adverse event intake, regional safety reporting and medical information support for healthcare professionals and regulators.
Preparation and submission of regulatory documents and interaction with regulatory authorities for approvals and specific plans (e.g., paediatric plans, marketing authorisations).
Identification, negotiation and management of in‑licensing and out‑licensing deals to expand therapeutic portfolios.
Technical and commercial redevelopment of established medicines through reformulation, repurposing or new dosage forms to improve patient outcomes and extend product lifecycle.
Market entry and commercial execution services including in‑house sales force deployment, distributor management and regional go‑to‑market strategies.
Management of CMO relationships for API manufacture, tolling and packing, and coordination with 3PLs and specialist distributors for global logistics.
Adverse event intake, regional safety reporting and medical information support for healthcare professionals and regulators.
Preparation and submission of regulatory documents and interaction with regulatory authorities for approvals and specific plans (e.g., paediatric plans, marketing authorisations).
Expertise Areas
- Life‑cycle management and drug repurposing
- In‑licensing, acquisitions and corporate development
- Global commercialisation and market access
- Supply chain and contract manufacturing management
Key Technologies
- Buccal film and alternative drug delivery formulations
- Combination therapeutics and precision medicine platforms
- Real‑world evidence and observational study methodologies
- Contract manufacturing and API tolling workflows
News & Updates
Pharmanovia announced a leadership update on 10th April 2025.
On 1st April 2025, Pharmanovia announced acquiring exclusive rights to a novel antipsychotic treatment.
On 21st February 2025, Pharmanovia announced an exclusive distribution agreement for Sunosi® in Eastern Europe.
On 2nd January 2025, Pharmanovia signed an in-licensing deal for a novel osteoporosis treatment.
An update on the company's leadership as of April 2025.
Details about Pharmanovia's acquisition of rights for a new antipsychotic treatment.
Pharmanovia announced a leadership update on 10th April 2025.
On 1st April 2025, Pharmanovia announced acquiring exclusive rights to a novel antipsychotic treatment.
On 21st February 2025, Pharmanovia announced an exclusive distribution agreement for Sunosi® in Eastern Europe.
On 2nd January 2025, Pharmanovia signed an in-licensing deal for a novel osteoporosis treatment.
An update on the company's leadership as of April 2025.
Details about Pharmanovia's acquisition of rights for a new antipsychotic treatment.